Lifecore Biomedical, Inc. Common Stock (LFCR) — Analysis Summary
Lifecore Biomedical, Inc. Common Stock (LFCR) has a market cap of $244.11M with year-over-year revenue growth of +0.5%. Net margin stands at -30.0%. The stock trades at a P/E ratio of -6.6.
Key Takeaways
- Revenue changed +0.5% year-over-year
- Net margin of -30.0%
- P/E ratio of -6.6
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, LFCR posted revenue growth of +0.5% and trades at a P/E of -6.6.
Lifecore Biomedical, Inc. Common Stock (LFCR)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Debt/EBITDA at 51.9x — highly leveraged, potential refinancing risk
D/E at 9.7x — extreme leverage
Net margin at -28.7% — significant losses
The latest filing shows negative free cash flow.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
382
Headquarters
CHASKA, MN
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.